Table 5

Correlation of the CEBPA mutations with clinical features, FAB subtypes, cytogenetics, and immunophenotypes

VariableTotal (n = 104)Distinct CEBPA mutated (n = 16)Others (n = 88)P
Age (y)
    >159616800.254
    ≤15808
Sex (male/female)61/4311/550/380.587
Hb (g/dL)*9.8±1.97.6±2.70.036
WBC (×1,000/μL)*16.5±123.719.4±84.70.293
Platelet (×1,000/μL)*21.0±19.933.5±46.90.065
BM blast (%)*66.2±24.251.0±31.70.126
LDH (IU)*997±12871009±12110.992
FAB subtype
    M1 + M26615 (23%)510.001
    Others38137
Cytogenetics
    Good310310.004
    Intermediate6115 (25%)46
    Poor10010
Antigen expression§
    CD722%73%12%<0.001
    CD1571%100%65%0.005
    CD3464%93%58%0.008
    HLA-DR71%93%67%0.034
  • Abbreviations: FAB, French-American-British; BM, bone marrow; Hb, hemoglobin.

  • * Mean ± SD.

  • Cytogenetic data are available from 102 patients. Good, including t(8;21), t(15;17), and inv(16); Poor, −5/del(5q), −7/del(7q), 3q anomaly, and complex (≥4) abnormalities. Intermediate, normal karyotype and other chromosomal abnormalities.

  • Thirty-one patients showed normal karyotype; 11 (35%) of them had CEBPA mutations.

  • § Percentage of patients with the antigen expression. There were no statistical differences in expression of other antigens, including myeloid associated antigens CD13, CD33, CD11b, CD14, and CD41 and lymphoid-associated antigens CD10, CD19, CD20, CD2, CD5, and CD56 between the two groups of patients.